Appendix 4E and Annual Report
Filed with ASX · · 73 pages · English
The loss for the Group after income tax for the reporting period was $4,389,667 (2015: $3,447,951). For further details relating to the current period’s results, refer to the Review of Operations contained within this document. Dividends No dividends have been paid or declared by the Group since the beginning of the current reporting period. No dividends were paid for the previous reporting period
Earlier from Immuron
- Immuron Expands Collaborate with US Navy
- US NIH to Fund Second IMC Fatty Liver Study - Pediatric NASH
- Travelan to be Stocked by US Distributor Medique Products
- Immuron to Cooperate with Universities on Autism Research
- Immuron to repay outstanding Convertible Note in cash
Later from Immuron
- Immurons $6M Rights Issue Closes Oversubscribed
- NASH Phase II Trial reaches 75% of Patient Recruitment
- Immurons NASH Phase II Trial Achieves 100 Patient Milestone
- Immuron Receives $1.6M R&D Tax Concession Refund
- NASH MOA Study commences with SanyalBio & Duke University
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron